Znanstveni rad - Izvorni znanstveni rad
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes & Endocrinology, 7 (2019), 8; 618-628. https://doi.org/10.1016/S2213-8587(19)30158-5

(ODYSSEY OUTCOMES Comm Investigators) Ray, Kausik K; Colhoun, Helen M; Szarek, Pećin; ... Reiner, Željko; ...; Peršić, Viktor; Tomulić, Vjekoslav; ...

Citirajte ovaj rad

Ray, K. K., Colhoun, H. M., Szarek, P., ... Reiner, Ž., Peršić, V. i Tomulić, V. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology, 7. (8), 618-628. doi: 10.1016/S2213-8587(19)30158-5

Ray, Kausik K, et al. "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial." The Lancet Diabetes & Endocrinology, vol. 7, br. 8, 2019, str. 618-628. https://doi.org/10.1016/S2213-8587(19)30158-5

Ray, Kausik K, Helen M Colhoun, Pećin Szarek, Željko ... Reiner, Viktor Peršić i Vjekoslav Tomulić. "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial." The Lancet Diabetes & Endocrinology 7, br. 8 (2019): 618-628. https://doi.org/10.1016/S2213-8587(19)30158-5

Ray, K. K., et al. (2019) 'Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial', The Lancet Diabetes & Endocrinology, 7(8), str. 618-628. doi: 10.1016/S2213-8587(19)30158-5

Ray KK, Colhoun HM, Szarek P, ... Reiner Ž, Peršić V, Tomulić V. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology [Internet]. 08.2019. [pristupljeno 19.06.2024.];7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5

K. K. Ray, H. M. Colhoun, P. Szarek, Ž. ... Reiner, V. Peršić i V. Tomulić, "Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial", The Lancet Diabetes & Endocrinology, vol. 7, br. 8, str. 618-628, Kolovoz 2019. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:611502. [Citirano: 19.06.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.